ESR1 and breast carcinoma: Consistent with this observations, treatment of ER+ breast cancer cells with the combination of RAD001 plus ABT-263 increased caspase-3/7 activity (Figure 3D) and decreased cell growth (Figure 3E) to a greater extent than either inhibitor alone.